Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)

NCT03600441 is registered in ClinicalTrials.gov with Xynomic Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03600441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03600441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 27, 2018
Completion date
December 31, 2029
Enrollment
139 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma